Oestradiol + progesterone

4 papers7 findings

PubChem 5757 PubChem 5994 ChEBI 16469 ChEBI 17026

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

3 independent labs in 2 countries

Funders: National Institute on Aging and others

Animals3
In silico1

Outcomes

Mortality

downin silico1

1 study

Oestradiol + progesterone decreases mortality in silico (-615 deaths per 10,000).
“was associated with 285 fewer cases of ASCVD, 18 more colon cancer cases, 46 more breast cancer cases, 183 fewer hip fractures, and 615 fewer deaths.”
In silicowith a uterus, 5 years usetransdermal E2 in combination with micronized progesterone5 yearsfemalesn = 10,000
Cost-Effectiveness Analysis of Menopausal Hormone Therapy
Obstetrics and gynecology13 Aug 2026

Cost-effectiveness

upin silico1

1 study

Oestradiol + progesterone improves cost-effectiveness in silico (-$127,738,990, +33,083 QALYs per 10,000).
“Micronized progesterone compared with no MHT was $127,738,990 less expensive, resulted in a gain of 33,083 QALYs”
In silicohypothetical patients with a uterus, 5 years usetransdermal E2 in combination with micronized progesterone5 yearsfemalesn = 10,000
Cost-Effectiveness Analysis of Menopausal Hormone Therapy
Obstetrics and gynecology13 Aug 2026

FOSB

upin mouse cells1

1 study

Oestradiol + progesterone increases FOSB in mouse cells.
“In vitro co-treatment with estradiol and progesterone increased FOSB and BACE1 levels, supporting the presence of a hormone-responsive regulatory link.”
Cellsin vitro co-treatment
Multiparity exacerbates Aβ accumulation and promotes cellular senescence in a mouse model of amyloidosis
Immunity & ageing : I & A29 Mar 2026